Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter phase II trial which primary objective is to assess the
anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199,
venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts:
- relapsed/refractory follicular lymphoma (FL) patients
- relapsed/refractory aggressive (DLBCL) lymphoma patients
- relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)